Alba Ribera1, Laura Soldevila1, Raul Rigo-Bonnin2, Fe Tubau3,4, Ariadna Padullés5, Joan Gómez-Junyent1, Javier Ariza1, Oscar Murillo6. 1. Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. 2. Clinical Laboratory Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. 3. Microbiology Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. 4. Ciber de Enfermedades Respiratorias ISCIII, Madrid, Spain. 5. Pharmacy Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. 6. Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. omurillo@bellvitgehospital.cat.
Abstract
Continuous infusion (CI) of beta-lactams could optimize their pharmacokinetic/pharmacodynamic indices, especially in difficult-to-treat infections. PURPOSE: To validate an easy-to-use method to guide beta-lactams dosage in CI (formula). METHODS: A retrospective analysis was conducted of a prospectively collected cohort (n = 24 patients) with osteoarticular infections caused by Gram-negative bacilli (GNB) managed with beta-lactams in CI. Beta-lactams dose was calculated using a described formula (daily dose = 24 h × beta-lactam clearance × target "steady-state" concentration) to achieve concentrations above the MIC. We correlated the predicted concentration (Cpred = daily dose/24 h × beta-lactam clearance) with the patient's observed concentration (Cobs) measured by UPLC-MS/MS (Spearman's coefficient). RESULTS: The most frequent microorganism treated was P. aeruginosa (21 cases; 9 MDR). Beta-lactams in CI were ceftazidime (n = 14), aztreonam (7), and piperacillin/tazobactam (3), mainly used in combination (12 with colistin, 5 with ciprofloxacin) and administered without notable side effects. The plasma Cobs was higher overall than Cpred; the Spearman correlation between both concentrations was rho = 0.6 (IC 95%: 0.2-0.8) for all beta-lactams, and rho = 0.8 (IC 95%: 0.4-1) for those treated with ceftazidime. CONCLUSIONS: The formula may be useful in clinical practice for planning the initial dosage of beta-lactams in CI, while we await a systematic therapeutic drug monitoring. The use of beta-lactams in CI was safe.
Continuous infusion (CI) of beta-lactams could optimize their pharmacokinetic/pharmacodynamic indices, especially in difficult-to-treat infections. PURPOSE: To validate an easy-to-use method to guide beta-lactams dosage in CI (formula). METHODS: A retrospective analysis was conducted of a prospectively collected cohort (n = 24 patients) with osteoarticular infections caused by Gram-negative bacilli (GNB) managed with beta-lactams in CI. Beta-lactams dose was calculated using a described formula (daily dose = 24 h × beta-lactam clearance × target "steady-state" concentration) to achieve concentrations above the MIC. We correlated the predicted concentration (Cpred = daily dose/24 h × beta-lactam clearance) with the patient's observed concentration (Cobs) measured by UPLC-MS/MS (Spearman's coefficient). RESULTS: The most frequent microorganism treated was P. aeruginosa (21 cases; 9 MDR). Beta-lactams in CI were ceftazidime (n = 14), aztreonam (7), and piperacillin/tazobactam (3), mainly used in combination (12 with colistin, 5 with ciprofloxacin) and administered without notable side effects. The plasma Cobs was higher overall than Cpred; the Spearman correlation between both concentrations was rho = 0.6 (IC 95%: 0.2-0.8) for all beta-lactams, and rho = 0.8 (IC 95%: 0.4-1) for those treated with ceftazidime. CONCLUSIONS: The formula may be useful in clinical practice for planning the initial dosage of beta-lactams in CI, while we await a systematic therapeutic drug monitoring. The use of beta-lactams in CI was safe.
Authors: Brad Moriyama; Stacey A Henning; Richard Childs; Steven M Holland; Victoria L Anderson; John C Morris; Wyndham H Wilson; George L Drusano; Thomas J Walsh Journal: Ann Pharmacother Date: 2010-04-06 Impact factor: 3.154
Authors: Angela Huttner; Stephan Harbarth; William W Hope; Jeffrey Lipman; Jason A Roberts Journal: J Antimicrob Chemother Date: 2015-07-17 Impact factor: 5.790
Authors: Jason A Roberts; Jennifer Paratz; Elizabeth Paratz; Wolfgang A Krueger; Jeffrey Lipman Journal: Int J Antimicrob Agents Date: 2007-04-17 Impact factor: 5.283
Authors: Elisabeth Krogsgaard Petersen; Pelle Hanberg; Martin Knudsen; Sara Kousgaard Tøstesen; Andrea René Jørgensen; Kristina Öbrink-Hansen; Kjeld Søballe; Maiken Stilling; Mats Bue Journal: Antibiotics (Basel) Date: 2022-07-07